Navigation Links
Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
Date:12/1/2011

CAMBRIDGE, Mass., Dec. 1, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced today that it has been awarded a one year $250,155 contract from the Department of Homeland Security (DHS) to develop an assay capable of detecting single molecules of botulinum toxin (BoNT) within complex environmental samples. In collaboration with the Botulinum Research Center (BRC) at UMass Dartmouth, Quanterix will develop and validate a high sensitivity assay capable of measuring extremely low levels of the BoNT agent. 

"The detection of low copy numbers of toxins and pathogenic bacteria for both clinical and environmental applications requires highly sensitive and rapid detection technologies capable of measuring relevant targets within complex sample mixtures," said David Duffy, Ph.D., Vice President of Research at Quanterix. "The 1,000-fold increase in sensitivity enabled by SiMoA will facilitate the direct detection of the toxins produced by active bacteria at much lower levels than is possible today. As a result, the detection of BoNT protein will provide important functional information on the presence of bacteria that complements nucleic acid identification. We believe that this approach could be extended to other bacteria and applications, for example, hospital acquired infections."

Dr. David Hodge from DHS added, "Quanterix's technology is expected to address a number of challenges currently faced by DHS for identifying active agents of bioterrorism, and offers great promise for a variety of applications in both the private and public sectors."

"Early and accurate detection of botulinum toxin is critical for our national security and public health. The ability to detect extremely low levels of toxin could significantly improve the diagnosis of botulism and better protect humans in biomedical and bio-defense scenarios," said Dr. Bal Ram Singh, BRC Director, and a world leader in the research and detection of botulinum toxin.

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.

About BRC

The Botulinum Research Center (BRC) was established by the University of Massachusetts Dartmouth under the leadership of Dr. Bal Ram Singh, professor of biophysical chemistry. BRC promotes research to create an understanding of the botulinum neurotoxins, their applications and the defenses against such toxins as biothreat agents. BRC was initiated as a national effort, in collaboration with many researchers in academia, government agencies and industry. Currently, it has an international advisory board consisting of scientists from the UK, Japan, Italy, Germany and the US. The state-of-the-art research building was opened on April 5, 2007. This two-story building houses world-class research facilities, including BSL3 labs, for Dr. Singh and for other research activities at UMass Dartmouth.  For more information on BRC, visit www.umassd.edu/brc.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Fifth-Generation PSA Test Enables More Sensitive Measurements Following Surgery
2. Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery
3. Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohns Disease
4. Quanterix and STRATEC Announce Strategic Partnership
5. Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability
6. Quanterix Announces New Technology Evaluation Agreement
7. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
8. Watsons Generic Yaz(R) Receives FDA Approval
9. UCSB professor receives award for graphene electronics research
10. iBio, Inc. Receives Notice from NYSE Amex Staff that Company Currently is Below Certain Continued Listing Standards
11. Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):